Perpetual Ltd’s Novo Nordisk NVO Stock Holding History

Perpetual Ltd’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-64,816	Closed	-$3.6M	–	455
2025 Q3	$3.6M	Buy	+64,816	New	+$3.79M	0.04%	156

Other funds holding NVO

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Perpetual Ltd's NVO Position: Q4 2025 in Review

Perpetual Ltd sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 64,816 shares — an estimated $3.6M sold.

Perpetual Ltd first reported a position in NVO in Q3 2025 and held it in 1 quarter. The position peaked at $3.6M in Q3 2025. 1,418 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

Perpetual Ltd reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
Perpetual Ltd sold 64,816 Novo Nordisk shares in Q4 2025, an estimated $3.6M.
Perpetual Ltd first reported a position in Novo Nordisk in Q3 2025 and held it in 1 quarter.
Perpetual Ltd's Novo Nordisk position peaked at $3.6M in Q3 2025.
1,418 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Perpetual Ltd's 13F filing for Q4 2025, filed 20 Jan 2026.